BUZZ-Tiziana Life Sciences rises as nasal MS drug shows promise in early study

Reuters02-25

BUZZ-<a href="https://laohu8.com/S/TIZAF">Tiziana Life</a> Sciences rises as nasal MS drug shows promise in early study

** Shares of biotech firm Tiziana Life Sciences TLSA.O rise 3% to $1.36 premarket

** Co says its experimental nasal drug for multiple sclerosis showed early signs of reducing brain inflammation in a small study

** Multiple sclerosis is an autoimmune nerve disorder where the immune system attacks the protective coating around nerves, disrupting signals between the brain and body

**  Co says all 10 patients in the early study had stable or improved disease with no serious side effects

**  Study showed reduced brain inflammation on scans and spinal fluid changes linked to lower inflammation and improved nerve protection, per co

**  Co is testing the drug in a larger mid-stage trial with results expected in 1H 2026 - TLSA

** Shares up ~114% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614084952?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 20:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614084952","market":"nz","top_or_hot":-1,"title":"BUZZ-Tiziana Life Sciences rises as nasal MS drug shows promise in early study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/TIZAF\">Tiziana Life</a> Sciences rises as nasal MS drug shows promise in early study </title></head><body><p>** Shares of biotech firm <a href=\"https://laohu8.com/S/TLSA\">Tiziana Life</a> Sciences <span>TLSA.O</span> rise 3% to $1.36 premarket     </p><p>** Co says its experimental nasal drug for multiple sclerosis showed early signs of reducing brain inflammation in a small study</p><p>** Multiple sclerosis is an autoimmune nerve disorder where the immune system attacks the protective coating around nerves, disrupting signals between the brain and body</p><p>**  Co says all 10 patients in the early study had stable or improved disease with no serious side effects</p><p>**  Study showed reduced brain inflammation on scans and spinal fluid changes linked to lower inflammation and improved nerve protection, per co</p><p>**  Co is testing the drug in a larger mid-stage trial with results expected in 1H 2026 - TLSA</p><p>** Shares up ~114% in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Tiziana Life Sciences rises as nasal MS drug shows promise in early study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Tiziana Life Sciences rises as nasal MS drug shows promise in early study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-25 20:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/TIZAF\">Tiziana Life</a> Sciences rises as nasal MS drug shows promise in early study </title></head><body><p>** Shares of biotech firm <a href=\"https://laohu8.com/S/TLSA\">Tiziana Life</a> Sciences <span>TLSA.O</span> rise 3% to $1.36 premarket     </p><p>** Co says its experimental nasal drug for multiple sclerosis showed early signs of reducing brain inflammation in a small study</p><p>** Multiple sclerosis is an autoimmune nerve disorder where the immune system attacks the protective coating around nerves, disrupting signals between the brain and body</p><p>**  Co says all 10 patients in the early study had stable or improved disease with no serious side effects</p><p>**  Study showed reduced brain inflammation on scans and spinal fluid changes linked to lower inflammation and improved nerve protection, per co</p><p>**  Co is testing the drug in a larger mid-stage trial with results expected in 1H 2026 - TLSA</p><p>** Shares up ~114% in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL4N3ZL13Z:1","article_id":"2614084952","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614084952","pubTimestamp":1772022837,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Tiziana Life Sciences rises as nasal MS drug shows promise in early study ** Shares of biotech firm Tiziana Life Sciences TLSA.O rise 3% to $1.36 premarket     ** Co says its experimental nasal drug for multiple sclerosis showed early signs of reducing brain inflammation in a small study** Multiple sclerosis is an autoimmune nerve disorder where the immune system attacks the protective coating around nerves, disrupting signals between the brain and body** Co says all 10 patients in the early study had stable or improved disease with no serious side effects** Study showed reduced brain inflammation on scans and spinal fluid changes linked to lower inflammation and improved nerve protection, per co** Co is testing the drug in a larger mid-stage trial with results expected in 1H 2026 - TLSA** Shares up ~114% in 2025  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TLSA":"Tiziana Life Sciences PLC"},"translate_title":"BUZZ-Tiziana Life Sciences因鼻多发性硬化症药物在早期研究中显示出前景而崛起","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLSA":0.9},"content_text":"BUZZ-Tiziana Life Sciences rises as nasal MS drug shows promise in early study ** Shares of biotech firm Tiziana Life Sciences TLSA.O rise 3% to $1.36 premarket     ** Co says its experimental nasal drug for multiple sclerosis showed early signs of reducing brain inflammation in a small study** Multiple sclerosis is an autoimmune nerve disorder where the immune system attacks the protective coating around nerves, disrupting signals between the brain and body**  Co says all 10 patients in the early study had stable or improved disease with no serious side effects**  Study showed reduced brain inflammation on scans and spinal fluid changes linked to lower inflammation and improved nerve protection, per co**  Co is testing the drug in a larger mid-stage trial with results expected in 1H 2026 - TLSA** Shares up ~114% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614084952","isCrawlerRequest":true}